Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CCL2 | P13500 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222502 | 1.00 | POLB (0.37) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL15664847 | 0.84 | POLB (0.37) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL8694188 | 0.83 | POLB (0.49) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL89374 | 0.83 | POLB (0.49) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL8697270 | 0.83 | POLB (0.49) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL28304038 | 0.82 | POLB (0.47) | POLBALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL27902025 | 0.80 | POLB (0.34) | POLBALDH1A1SMN1; SMN2KDM4ERET | |
| SCHEMBL6700611 | 0.80 | POLB (0.39) | POLBALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL50555 | 0.79 | POLB (0.37) | POLBALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL29059172 | 0.79 | POLB (0.37) | POLBALDH1A1SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180289654-A1 | Therapeutic Compositions | PEPLIN RESEARCH PTY LIMITED (AU) | 2018-10-11 | — | — | US | claimed |
| US-9895334-B2 | Treatment of virally induced lesions | LEO LABORATORIES LIMITED (IE) | 2018-02-20 | — | — | US | claimed |
| US-9861603-B2 | Therapeutic compositions | LEO LABORATORIES LIMITED (IE) | 2018-01-09 | — | — | US | claimed |
| US-9833428-B2 | Therapeutic compositions | LEO LABORATORIES LIMITED (IE) | 2017-12-05 | — | — | US | claimed |
| US-9833429-B2 | Therapeutic compositions | LEO LABORATORIES LIMITED (IE) | 2017-12-05 | — | — | US | claimed |
| US-9820959-B2 | Therapeutic compositions | LEO LABORATORIES LIMITED (IE) | 2017-11-21 | — | — | US | claimed |
| US-20140357712-A1 | THERAPEUTIC COMPOSITIONS | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | US | claimed |
| US-20140249218-A1 | ADMINISTRATION OF INGENOL MEBUTATE | LEO LABORATORIES LIMITED (IE) | 2014-09-04 | — | — | US | claimed |
| US-8735375-B2 | Therapeutic compositions | LEO LABORATORIES LIMITED (IE) | 2014-05-27 | — | — | US | claimed |
| US-8716271-B2 | Therapeutic compositions | LEO LABORATORIES LIMITED (IE) | 2014-05-06 | — | — | US | claimed |
| US-20120309827-A1 | THERAPEUTIC COMPOSITIONS | LEO LABORATORIES LIMITED (IE) | 2012-12-06 | — | — | US | claimed |
| US-20120295970-A1 | THERAPEUTIC COMPOSITIONS | LEO LABORATORIES LIMITED (IE) | 2012-11-22 | — | — | US | claimed |
| US-20120295971-A1 | THERAPEUTIC COMPOSITIONS | LEO LABORATORIES LIMITED (IE) | 2012-11-22 | — | — | US | claimed |
| EP-2399571-A1 | Therapeutic compositions comprising ingenol-3-angelate | Peplin Research Pty Ltd. (AU) | 2011-12-28 | — | — | EP | claimed |
| US-20090292017-A1 | THERAPEUTIC COMPOSITIONS | PEPLIN RESEARCH PTY LIMITED | 2009-11-26 | — | — | US | claimed |
| EP-1988877-A2 | THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE | Peplin Research Pty Ltd. (AU) | 2008-11-12 | — | — | EP | claimed |
| EP-1951221-A1 | USE OF ANGELOYL-SUBSTITUTED INGENANES IN COMBINATION WITH OTHER AGENTS TO TREAT CANCER | Peplin Research Pty Ltd. (AU) | 2008-08-06 | — | — | EP | claimed |
| US-20080069809-A1 | Compositions and methods for the diagnosis and treatment of cancer | PEPLIN RESEARCH PTY LTD (AU) | 2008-03-20 | — | — | US | claimed |
| WO-2007068963-A2 | THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE | PEPLIN RESEARCH PTY LTD (AU) | 2007-06-21 | — | — | WO | claimed |
| WO-2007053912-A1 | USE OF ANGELOYL-SUBSTITUTED INGENANES IN COMBINATION WITH OTHER AGENTS TO TREAT CANCER | PEPLIN RESEARCH PTY LTD (AU) | 2007-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292017-A1 | THERAPEUTIC COMPOSITIONS | TP53, ERGIC1, MCL1 | POLB 4024/4885ALDH1A1 1407/4885SMN1; SMN2 2616/4885 |
| US-20120295971-A1 | THERAPEUTIC COMPOSITIONS | TP53, ERGIC1, MCL1 | POLB 4024/4885ALDH1A1 1407/4885SMN1; SMN2 2616/4885 |
| US-20120309827-A1 | THERAPEUTIC COMPOSITIONS | TP53, ERGIC1, MCL1 | POLB 4024/4885ALDH1A1 1407/4885SMN1; SMN2 2616/4885 |
| US-20080069809-A1 | Compositions and methods for the diagnosis and treatment of cancer | TP53, MKI67, ANXA5 | POLB 448/4885ALDH1A1 808/4885SMN1; SMN2 2478/4885 |
| US-20140249218-A1 | ADMINISTRATION OF INGENOL MEBUTATE | PDE8B, PRKAR2B, PRKCB | POLB 1561/4885ALDH1A1 3196/4885SMN1; SMN2 4628/4885 |
| US-20180289654-A1 | Therapeutic Compositions | TP53, ERGIC1, MCL1 | POLB 4024/4885ALDH1A1 1407/4885SMN1; SMN2 2616/4885 |
| US-20120295970-A1 | THERAPEUTIC COMPOSITIONS | TP53, ERGIC1, MCL1 | POLB 4024/4885ALDH1A1 1407/4885SMN1; SMN2 2616/4885 |
| US-20140357712-A1 | THERAPEUTIC COMPOSITIONS | TP53, ERGIC1, MCL1 | POLB 4024/4885ALDH1A1 1407/4885SMN1; SMN2 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.